Louisiana State Employees Retirement System Buys New Shares in ANI Pharmaceuticals, Inc. $ANIP

Louisiana State Employees Retirement System purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $615,000.

Other large investors also recently bought and sold shares of the company. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after buying an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after acquiring an additional 423 shares during the last quarter. Jane Street Group LLC acquired a new position in ANI Pharmaceuticals in the first quarter valued at $2,706,000. Finally, Norges Bank purchased a new stake in ANI Pharmaceuticals during the second quarter valued at about $625,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Up 1.1%

NASDAQ:ANIP opened at $85.99 on Wednesday. The business’s 50-day moving average is $81.29 and its two-hundred day moving average is $79.47. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a 12 month low of $62.60 and a 12 month high of $99.50. The firm has a market capitalization of $1.96 billion, a PE ratio of 21.77 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the previous year, the firm posted $1.70 earnings per share. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANIP has been the topic of a number of research reports. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

Insider Activity

In other news, Director Thomas Haughey sold 2,000 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director directly owned 38,878 shares of the company’s stock, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the transaction, the chief financial officer owned 177,543 shares of the company’s stock, valued at $15,268,698. This trade represents a 1.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 85,179 shares of company stock worth $6,720,651 in the last ninety days. 8.10% of the stock is currently owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.